These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24845976)

  • 1. Identification and characterization of bovine programmed death-ligand 2.
    Nishimori A; Konnai S; Ikebuchi R; Okagawa T; Nakajima C; Suzuki Y; Mingala CN; Murata S; Ohashi K
    Microbiol Immunol; 2014 Jul; 58(7):388-97. PubMed ID: 24845976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.
    Nishimori A; Konnai S; Okagawa T; Maekawa N; Ikebuchi R; Goto S; Sajiki Y; Suzuki Y; Kohara J; Ogasawara S; Kato Y; Murata S; Ohashi K
    PLoS One; 2017; 12(4):e0174916. PubMed ID: 28445479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection.
    Zhang E; Zhang X; Liu J; Wang B; Tian Y; Kosinska AD; Ma Z; Xu Y; Dittmer U; Roggendorf M; Yang D; Lu M
    PLoS One; 2011; 6(10):e26196. PubMed ID: 22022563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade.
    Ikebuchi R; Konnai S; Shirai T; Sunden Y; Murata S; Onuma M; Ohashi K
    Vet Res; 2011 Sep; 42(1):103. PubMed ID: 21943148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Increased expressions of programmed death 1 (PD-1) and its ligands in peripheral CD3(+) T cells and CD19(+) B cells in patients with hepatocellular carcinoma].
    Liu W; Chai L; Liang J; Lu Z; Yang S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Sep; 32(9):1243-7. PubMed ID: 27609582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitro.
    Ikebuchi R; Konnai S; Okagawa T; Yokoyama K; Nakajima C; Suzuki Y; Murata S; Ohashi K
    Vet Res; 2013 Jul; 44(1):59. PubMed ID: 23876077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN-γ production via PD-1/PD-L1 blockade in bovine mycoplasmosis.
    Goto S; Konnai S; Okagawa T; Nishimori A; Maekawa N; Gondaira S; Higuchi H; Koiwa M; Tajima M; Kohara J; Ogasawara S; Kato Y; Suzuki Y; Murata S; Ohashi K
    Immun Inflamm Dis; 2017 Sep; 5(3):355-363. PubMed ID: 28544524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-γ decreased the suppressive function of CD33
    Zhan X; Hu S; Wu Y; Li M; Liu T; Ming S; Wu M; Liu M; Huang X
    Mol Immunol; 2018 Feb; 94():107-120. PubMed ID: 29291452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular cloning and expression analysis of bovine programmed death-1.
    Ikebuchi R; Konnai S; Sunden Y; Onuma M; Ohashi K
    Microbiol Immunol; 2010 May; 54(5):291-8. PubMed ID: 20536726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term use of indomethacin leads to poor prognoses through promoting the expression of PD-1 and PD-L2 via TRIF/NF-κB pathway and JAK/STAT3 pathway to inhibit TNF-α and IFN-γ in hepatocellular carcinoma.
    Xu P; Sun Z; Wang Y; Miao C
    Exp Cell Res; 2015 Sep; 337(1):53-60. PubMed ID: 26162855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune inhibitory function of bovine CTLA-4 and the effects of its blockade in IFN-γ production.
    Watari K; Konnai S; Maekawa N; Okagawa T; Suzuki Y; Murata S; Ohashi K
    BMC Vet Res; 2019 Oct; 15(1):380. PubMed ID: 31665022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 blockade inhibits lymphocyte apoptosis and restores proliferation and anti-viral immune functions of lymphocyte after CP and NCP BVDV infection in vitro.
    Liu Y; Liu S; He B; Wang T; Zhao S; Wu C; Yue S; Zhang S; He M; Wang L; Huang W; Shi T; Zhu Z
    Vet Microbiol; 2018 Nov; 226():74-80. PubMed ID: 30389046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combined cytotoxic T-lymphocyte antigen 4 and programed death 1 ligand-receptor blockade on interferon-gamma production in bovine leukemia virus-infected cattle.
    Borovikov S; Tursunov K; Adish Z; Tokhtarova L; Mukantayev K
    Vet World; 2024 Aug; 17(8):1672-1679. PubMed ID: 39328455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The high expression level of programmed death-1 ligand 2 in oral lichen planus and the possible costimulatory effect on human T cells.
    Du GH; Qin XP; Li Q; Zhou YM; Shen XM; Tang GY
    J Oral Pathol Med; 2011 Aug; 40(7):525-32. PubMed ID: 21457347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3.
    Seko Y; Yagita H; Okumura K; Azuma M; Nagai R
    Cardiovasc Res; 2007 Jul; 75(1):158-67. PubMed ID: 17434153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells.
    Gu YZ; Xue Q; Chen YJ; Yu GH; Qing MD; Shen Y; Wang MY; Shi Q; Zhang XG
    Hum Immunol; 2013 Mar; 74(3):267-76. PubMed ID: 23261407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis.
    Alvarez IB; Pasquinelli V; Jurado JO; Abbate E; Musella RM; de la Barrera SS; García VE
    J Infect Dis; 2010 Aug; 202(4):524-32. PubMed ID: 20617899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals.
    Philips EA; Garcia-España A; Tocheva AS; Ahearn IM; Adam KR; Pan R; Mor A; Kong XP
    J Biol Chem; 2020 Apr; 295(14):4372-4380. PubMed ID: 31882544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis.
    Javan MR; Aslani S; Zamani MR; Rostamnejad J; Asadi M; Farhoodi M; Nicknam MH
    Iran J Allergy Asthma Immunol; 2016 Aug; 15(4):296-302. PubMed ID: 27921410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
    Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
    Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.